http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
-
Acadia Pharma (ACAD): Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating DAYBUE in Patients with Rett Syndrome Published
-
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
-
Acadia Pharma (ACAD) Presents DAYBUE Real-World Evidence and Additional Data in Rett Syndrome
-
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
-
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
-
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
-
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
-
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
-
Acadia Pharma (ACAD) Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
-
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
-
Acadia Pharma (ACAD) Appoints Elizabeth H. Z. Thompson as Head of R&D
-
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
-
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
-
Acadia Pharma (ACAD) Reports Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin
-
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
-
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
-
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
-
Acadia Pharma (ACAD) Appoints Jennifer J. Rhodes as Chief Legal Officer and Secretary, Kimberly J. Manhard as SVP, Global Strategic Planning and Execution
-
Acadia Announces Additions to Executive Team
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharma (ACAD) Announces the Passing of Former President Srdjan (Serge) Stankovic
-
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
-
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharma (ACAD) Reports Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction Claims Regarding NUPLAZID
-
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
-
Acadia Pharma (ACAD) Reports Delaware Federal District Court Ruled in Favor of Acadia in NUPLAZID Patent Litigation
-
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
-
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
-
Acadia Pharma (ACAD) Initiates Phase 2 Clinical Trial of ACP-204
-
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
-
Acadia Pharma (ACAD) Announces Departure of Doug Williamson, EVP and Head of Research and Development
-
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
-
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
-
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
-
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
